Advertisement

Topics

Latest Top Pharmaceutical Companies in South Korea NewsRSS

13:01 EDT 19th September 2018 | BioPortfolio

Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects

BUFFALO, N.Y., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, and its business partner, Hanmi Pharmaceutical, today announced a strategic realignment of their joint projects to further explore and develop those p...

Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea

License includes C$13 million in non-dilutive milestone payments and a double-digit royalty to Antibe Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd...

Sam Chun Dang Pharm Co Ltd 000250 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummarySam Chun Dang Pharm Co Ltd SCD is a manufacturer of prescription medicines. The company offers products in the therapeutic areas of ophthalmology, cardiovasculars, endocrinology, gastrointestines, antibacterials, antifungals, antivirals, respiratory, antiinflammatories, antihistamines, musculoskeletals, and vitamines. Its ophthalmic drugs provides dry eye therapies, antibiotic eye drops, gl...

Hanmi to Streamline Clinical Trials and Bolster Quality of Results with Medidata Cloud

Leading R&D focused Korean pharmaceutical company expands use of Intelligent Platform for Life Sciences Adds Edge Central Monitoring with Machine Learning and Rave eCOA/ePRO Hanmi streamlines management of clinical trial risk and mobile patient data Full Story Hanm...

Chong Kun Dang Pharmaceutical Corp 185750 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryChong Kun Dang Pharmaceutical Corp CKD Pharma manufactures, distributes, imports and exports prescription drugs, active pharmaceutical ingredients APIs, overthecounter OTC drugs, health supplements and consumer health products. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colors; aerosols; mat vaporizers and mo...

Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryHanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company's prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others. Hanmi Pharma...

Hanmi Pharmaceuticals Co Ltd 128940 Medical Equipment Deals and Alliances Profile [Report Updated: 11052018] Prices from USD $250

SummaryHanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company's prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others. Hanmi Pharma...

Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23042018] Prices from USD $250

SummaryIldong Pharmaceutical Co Ltd IPC is a manufacturer of pharmaceutical products. The company provides finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others. Its products include antihistamine drugs, antineoplastic agents, antifungals and antivirals, blood circulation, endocrine and metabolic system, cardiovascular system, central nervous system, ...

Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China

Additional milestone and sales payments total up to $72.5M plus double-digit royalties Recently signed CMS agreement adds to four existing distribution agreements in Canada, South Korea and three countries in Europe (Spain, Switzerland and Austria) Can-Fite BioPharma Ltd.

Daewoong Pharmaceutical Co Ltd 069620 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryDaewoong Pharmaceutical Co Ltd Daewoong Pharma is one of the leading manufacturers and distributors of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, medical devices, cosmetics, health foods and APIs. The company produces products in the forms of tablets, capsules, ointments, injections, liquids and sprays. It offers its products for the therapeutic conditions...

Genome Editing Biotech EdiGene Names Dong Wei, Ph.D., MBA as its Chief Executive Officer

EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced that it has named Dong Wei, Ph.D., MBA, an experienced biopharmaceutical executive, as its chief executive officer. Dr. Dong Wei brings extensive experiences in strategic plann...

Kwang Dong Pharmaceutical Co Ltd 009290 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryKwang Dong Pharmaceutical Co Ltd Kwang Dong is a drug manufacturer that develops, manufactures and supplies pharmaceuticals, health drinks and supplements. The company's pharmaceutical products comprise OTC drugs, ETC drugs, general supplements, OTC drinks, consumer drinks, functional food and traditional health foods. Its products find application in the therapeutic areas of gastrointestin...

Yuhan Corp 000100 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummaryYuhan Corp Yuhan researches, develops, manufactures and markets pharmaceutical products. The company offers API's and intermediates for antibiotic, antiviral, antifungal, antiinflammatory, antidiabetic, antiHIV, antiHCV, betalactase inhibitors, PEGlyated compounds and antihistamines. It offers finished goods for the treatment of coronary artery disease, hypertension, hyperlipidemia, cerebra...

Sam Chun Dang Pharm Co Ltd 000250 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11072018] Prices from USD $250

SummarySam Chun Dang Pharm Co Ltd SCD is a manufacturer of prescription medicines. The company offers products in the therapeutic areas of ophthalmology, cardiovasculars, endocrinology, gastrointestines, antibacterials, antifungals, antivirals, respiratory, antiinflammatories, antihistamines, musculoskeletals, and vitamines. Its ophthalmic drugs provides dry eye therapies, antibiotic eye drops, gl...

Yuhan Corp 000100 Financial and Strategic SWOT Analysis Review [Report Updated: 11072018] Prices from USD $125

Yuhan Corp 000100 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your bus...

OliX, a RNAi therapeutics developer, gets approval for KOSDAQ listing

SUWON, South Korea, July 23, 2018 /PRNewswire/ -- OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, has successfully completed its public listing on the Korea Securities Dealer Automated Quotation (KOSDAQ) in the Korean stock market on July 18. On its first day of trading, shares of OliX closed at KRW65,600 ($58) per share with its market capitalization stand...

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

Genosco, a clinical-stage biotechnology company focused in immunology and oncology, announced data from a Phase 1/2 study evaluating lazertinib (YH25448, GNS-1480) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Lazertinib (YH25448

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

Genosco, a clinical-stage biotechnology company focused in immunology and oncology, today announced that the abstract from a Phase 1/2 study evaluating YH25448 (GNS-1480) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) is now available on the website of the 2018 American Society of Clinical Oncology (ASCO) Annual

Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs

-- Strategic focus on unleashing therapeutic potential of specific orphan GPCRs, including novel family of Mas-Related G-Protein Receptors (Mrgprs) -- -- Opportunity to pursue novel therapeutics for a broad range of indications; initial focus on neuro-immuno-inflammatory and autoreactive diseases -- -- Series A investors include Th...

Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of pozi...

Global and China LModified Petroleum Resin C9 Market Research by Company, Type Application 20132025 [Report Updated: 06032018] Prices from USD $2000

SummaryMarket Segment as follows:By Type Silicon Wafer PCB Laminate Photoresist OthersBy Application Paint Industries Adhesive Rubber and Tyre Printing Ink OthersBy Company LESCO Bater CHANGYU China Mk Group Yangzhou Sunchem Shandong Qilong Chemical Puyang Shenghong Chemical Neville Chemical Company Dong Mai BASF Puyang Changyu Petroleum ...

Dotmatics Kicks Off Global 2018 Symposia

Robust series includes eight events in America, Australia, Europe, Japan and Korea Dotmatics, a leading provider of scientific informatics solutions and services, today announced this year’s symposia line up. The company will host symposiums in Boston, Brisbane, Cambridge, Melbourne, Osaka, San Francisco, Seoul and Tokyo. Dotma...

Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and clinical studies evaluating poziotinib in HER2 exon 20 mutations in non-small cell lung cancer (NSCLC) and summarizi...

Hanmi scraps lung cancer drug due to AstraZeneca rival, reports say

Olita showed promise but fizzled amid partnership and safety setbacks, and ultimately failed to compete with AstraZeneca's Tagrisso.

20152023 World OxygenFree Copper Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 24022018] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.Market Segment as follows:By Region / Countries North America U.S., Canada, Mexico Europe Germany, U.K., France, Italy, Russia, Spain etc South Americ...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in South Korea market research data and corporate reports here